EyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants
July 30, 2015 18:08 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., July 30, 2015 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing...
EyeGate Pharma Receives USPTO Notice of Allowance for Proprietary Dexamethasone Phosphate Formulation
July 24, 2015 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., July 24, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Treats First Patient in Phase 1b / 2a Trial of EGP-437 in Macular Edema
July 14, 2015 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
First Clinical Trial Evaluating EyeGate® II Delivery System in Posterior of Eye
WALTHAM, Mass., July 14, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate" or the...
EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis
July 10, 2015 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., July 10, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis
May 04, 2015 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 4, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharmaceuticals Reports Full Year 2014 Financial Results
March 31, 2015 17:40 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., March 31, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (OTCBB:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and...
Eyegate Pharmaceuticals Names Michael B. Raizman, MD, Consulting Chief Medical Officer
March 02, 2015 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) ("EyeGate"), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics...
Eyegate Pharmaceuticals, Inc. Announces Closing of Initial Public Offering of Approximately $4,100,000 of Common Stock
February 19, 2015 12:28 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (OTCQB:EYEGV) ("EyeGate"), a specialty pharmaceutical company that focuses on developing and commercializing...
Eyegate Pharmaceuticals, Inc. Prices $4,100,000 Initial Public Offering
February 12, 2015 18:29 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (OTCQB:EYEGV) ("EyeGate"), a specialty pharmaceutical company that focuses on developing and commercializing...